Tai Diagnostics, a US-based developer of organ transplant aftercare technology, closed a $10m series A round featuring biopharmaceutical company and strategic partner United Therapeutics on Monday.
Founded in 2015, Tai Diagnostics is working on a monitoring procedure for patients who have undergone an organ transplant.
Tai’s approach specifically identifies the transferred DNA that has been damaged, potentially acting as a more reliable indicator of organ rejection than the tissue biopsies often used today.
The funding will go to research and development ahead of clinical studies and an envisaged commercial launch. United and Tai have formed a collaboration agreement alongside the funding.
The company is a spinout from the Medical College of Wisconsin and its technology is based on research by Michael Mitchell, a professor in cardiothoracic surgery, and Aoy Tomita-Mitchell, a professor of surgery and congenital heart surgery.
Tai Diagnostics has now raised $21m in total, the company said. That figure includes $8.3m raised over two tranches in 2015, according to a securities filing.